Xiang-Guo Li
Associate Professor
Turku PET Centre, University of Turku xiali@utu.fi Kiinamyllynkatu 10 Turku ORCID identifier: https://orcid.org/0000-0002-9118-7223 |
Radiochemistry, Radiopharmaceuticals, PET imaging, New drug development
Radiochemistry, Radiopharmaceuticals, InFLAMES Flagship
I am a radiochemist and medicinal chemist working at Turku PET Centre, University of Turku, Finland. I received my PhD degree from the Institute of Biomedicine, Faculty of Medicine, University of Turku, in 2008. Then I was at a Post-doctoral position funded by the Academy of Finland during 2010-2012. I received my Docentship in 2012 from University of Turku. Since 2013, I have been working at Turku PET Centre. At present, I work as an Assistant Professor in Radiochemistry, and Principal Investigator in the InFLAMES Research Flagship.
Basic research in radiochemistry including methodological development for radiosynthesis and radiolabeling techniques. We have been able to radiolabel many types of molecules including small organic compounds, peptides, antibody and antibody fragments, oligonucleotides, oligosaccharides etc.
Development of new radiopharmaceuticals for PET imaging of inflammatory diseases and immunological diseases.
The radiolabeled molecules are for imaging diseases or for studying disease machanisms with PET.
I teach in the courses of Radiopharmaceutical Chemistry, Radiolabeling techniques, Measuring techniques in radiochemistry, PET Basics, and supervise BSc, MSc and PhD students.
- Evaluation of a clinically efficient [18F]FDG PET/CT protocol: short dynamic and two-phase static imaging for differentiating malignant pulmonary lesions (2026)
- EJNMMI Research
(A1 Refereed original research article in a scientific journal) - Exclusively chemoselective S-acylation for peptide radiolabeling using [18F]fluoronicotinic acid 4-nitrophenyl ester as a prosthetic compound (2026)
- ACS Omega
(A1 Refereed original research article in a scientific journal) - Folate receptor β-targeted Positron emission tomography imaging of activated macrophages in experimental myocardial infarction (2026)
- Journal of Nuclear Cardiology
(A1 Refereed original research article in a scientific journal) - Intracranial Human BT12 Glioblastoma Xenograft is [18F]FET PET Negative but 6-[18F]Fluoronicotinic Acid PET Positive: Exploring a Novel Approach for Clinical Glioblastoma Imaging (2026)
- Molecular Pharmaceutics
(A1 Refereed original research article in a scientific journal) - [18F]Fluoronicotinic-Acid-Conjugated Folate as a Novel Candidate Positron Emission Tomography Tracer for Inflammation (2025)
- ACS Omega
(A1 Refereed original research article in a scientific journal) - Comparing Two Folate Receptor β-Targeted Tracers in a Rat Model of Experimental Autoimmune Myocarditis (2025)
- ACS pharmacology & translational science
(A1 Refereed original research article in a scientific journal) - Highlight selection of radiochemistry and radiopharmacy developments by editorial board (2025)
- EJNMMI Radiopharmacy and Chemistry
(Other publication) - Longitudinal monitoring of nanofibrillar cellulose hydrogel medical implants in mice using positron emission tomography (2025)
- European Journal of Pharmaceutical Sciences
(A1 Refereed original research article in a scientific journal) - Macrophage mannose receptor CD206-targeted PET imaging in experimental acute myocardial infarction (2025)
- EJNMMI Research
(A1 Refereed original research article in a scientific journal) - Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules (2025)
- EJNMMI Radiopharmacy and Chemistry
(A1 Refereed original research article in a scientific journal)



